Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.37 |
| ▸ | IKBKB | O14920 | 2/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21074663 | 0.79 | CHRNB2 (0.66) | CHRNB2CHRNA4 | |
| SCHEMBL19275554 | 0.76 | HTR2A (0.50) | HTR2ACHRNB2CHRNA4HTR2C | |
| SCHEMBL23153170 | 0.68 | CHRNB2 (0.68) | CHRNB2CHRNA4 | |
| SCHEMBL22795541 | 0.67 | MAPK11 (0.53) | MAPK14MAPK11MAPK13RAF1MAPK9 | |
| SCHEMBL22005019 | 0.67 | CHEK1 (0.42) | HTR2ACHRNB2CHRNA4CHEK1CCNA2 | |
| SCHEMBL3255979 | 0.66 | HTR3A (0.48) | MAPK14MAPK11MAPK13RAF1MAPK9 | |
| SCHEMBL26938735 | 0.66 | HTR2A (0.54) | HTR2ACHRNB2CHRNA4HTR2C | |
| Hydrochloric Acid SCHEMBL2320460 | 0.66 | MAPK11 (0.50) | MAPK14MAPK11MAPK13RAF1MAPK9 | |
| SCHEMBL21074662 | 0.66 | CHRNB2 (0.59) | CHRNB2CHRNA4 | |
| SCHEMBL1771575 | 0.65 | HTR2A (0.52) | HTR2AIKBKBHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169264-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | HOWARD HUGHES MEDICAL INSTITUTE | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169264-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | GRIK4, GRIK2, GRIK5 | MAPK14 4200/4885MAPK11 4289/4885MAPK13 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.